DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/4ccpnn/large_volume) has announced the addition of the "Large Volume Wearable Injectors - 2nd Edition" report to their offering.
The injectable drug delivery market holds significant potential for the future. From the conventional syringes with vials and painful needles to the modern-day pre-filled syringes, pen-injectors, needle free injectors and auto-injectors, the market has come a long way. The rising prevalence of chronic diseases is one of the key factors driving the companies to develop systems that allow patients to self-administer drugs. Taking the concept of self-injectors to a new stratum, Large volume Wearable Injectors' have surfaced recently. Also known as bolus injectors and non-insulin patch pumps, these devices not only offer a range of benefits to the end users but also provide a number of additional benefits to other stakeholders in the industry.
One of the main drivers for the perceived growth of these injectors is the large number of biologics currently under development. A majority of these molecules are highly viscous and are required to be delivered in volumes of greater than 1 ml. The absence of devices which can safely administer these drugs is currently a big unmet need in the market. However, the early signs are encouraging. Despite the uncertainties related to the device development and approval, many companies are investing time, money and resources to develop novel devices. Some customized drug-device combinations are currently being developed for specific drugs such as Herceptin, AMG-145 and Furosemide. In addition, pharma companies have many undisclosed programs which are likely to provide the necessary growth impetus in the near future.
- In total, over 15 large volume wearable drug delivery devices (including variants) currently under development have been identified during our research.
- Approximately 53% of these devices operate electronically. Other modes of operation include mechanical, hydrogel and hydraulic. Many of these injectors have additional features such as an audio / visual panel making their usage very easy for the end users.
- The range of volume these devices can cater to is as high as 30 ml. The first commercial launch is anticipated to take place in 2015/2016. In our research, we have profiled five drugs which are currently undergoing trials for delivery via large volume injectors.
- Pharma companies also have many undisclosed research programs.We have identified about 30 biologics which are likely to be immediate targets for preparation of subcutaneous formulation and delivery via large volume wearable injectors. In addition to these highly likely candidates, there are more than 100 other drug-disease combinations which are expected to draw interest in the short-mid term.
- The manufacturer's landscape is still evolving. In addition the established firms such as Becton Dickinson and West Pharma, many start-ups including Unilife, Sensile Medical, SteadyMed Therapeutics and Enable Injections are heading towards the pole position
- The growth in biologics will be one of the key drivers for the emergence of large volume wearable injectors. Around 50% of the top 100 selling drugs are expected to be biologics by 2016; biologics are estimated to contribute 27% of the total drugs market by 2020.
- Other key reasons for the growth of bolus injectors include their potential to act as life cycle management tool, increasing trend towards drug self-administration and the overall drive towards cheaper healthcare costs.
Key Topics Covered:
2. EXECUTIVE SUMMARY
4. OVERVIEW AND MARKET BACKGROUND
5. TARGET DRUGS FOR LARGE VOLUME WEARABLE INJECTORS
6. CASE STUDIES
7. PRODUCT PROFILES
8. MARKET SIZE AND FORECAST
9. SWOT ANALYSIS
10. COMPANY PROFILES
11. INTERVIEW TRANSCRIPTS
13. APPENDIX 1: Tabulated Data
14. APPENDIX 2: List of Companies and Organizations
For more information visit http://www.researchandmarkets.com/research/4ccpnn/large_volume